US CMS Providing Medicaid Coverage For COVID-19 Tests, But Congressman Still Sees Gaps For Testing Working Poor

The US Centers for Medicare and Medicaid Services (CMS) created a new billing code to help diagnose coronavirus in its beneficiaries on 5 March, as well as fact sheets on medical care and transport of COVID-19 patients, but patients who get their health care through low-cost insurance plans may not be able to afford the testing, said a House Committee chairman.

Nurse holding test tube with blood for 2019-nCoV analyzing. Novel Chinese Coronavirus blood test Concept.

The CMS has given health care facilities a billing code for its beneficiaries’ coronavirus diagnostics – but working poor patients who have slipped through the cracks between Medicaid and Affordable Care Act coverage may find their “junk” plans don’t cover the test, said Rep. Richard Neal, D-MA.

“At CMS, we continue to leverage every tool at our disposal in responding to COVID-19,” said CMS Administrator Seema Verma in announcing the new billing code for use by Medicare,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By 

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

Plans For Specific EU Orphan And Pediatric Device Expert Panel Need To Go Further

 

Moves are at last underway for a more specific focus on orphan and pediatric devices. They are a start; but experts are calling for more to support this sector.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.